Most recently, Chris was CEO of AxioMx, a portfolio company sold to Abcam Plc in November, 2015. Throughout his career, he has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. Chris served as President and Chief Executive Officer of 454 Life Sciences from February 2005 through September 2011, and managed the integration with Roche Diagnostics following its acquisition in 2007. Previously, he served as Executive Vice President of CuraGen from November 1999, where he oversaw bioinformatics, strategic business development, and collaborative research. Prior to joining CuraGen, Chris spent over two years as Chief Executive Officer of Havas Interactive (formerly Cendant Software), a leading international software developer. He earned his B.S. Magna Cum Laude with a dual major in economics and engineering and applied science from Yale University and his M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology. Chris serves on the boards of Sacred Heart University and the CT Yankee Council, Boy Scouts of America.